Table 5.

24 Week treatment failure-free survival (TFFS) – n (%).

	carboplatin + paclitaxel		cisplatin + capecitabine		Odds Ratio (95% CI)	p value
Squamous cell
Patients randomised	25		27
Died/progressed prior to week 24 scana	3	12.0	0	0.0
Valid CT scan doneb	22	88.0	27	100.0
Progression outside RT volume	4	16.0	2	7.4
Valid endoscopy donec	21	84.0	23	85.2
Residual/persistent disease	3	12.0	0	0.0
Response assessable	25	100.0	27	100.0
Failure-free	17	68.0	25	92.6	0.14 (0.02–0.81)	0.028d
Failure	8	32.0	2	7.4
Adenocarcinoma and undifferentiated
Patients randomised	6		5
Died/progressed prior to week 24 scana	1	16.7	1	20.0
Valid CT scan doneb	5	83.3	4	80.0
Progression outside RT volume	0	0.0	0	0.0
Valid endoscopy donec	5	83.3	3	60.0
Residual/persistent disease	1	16.7	0	0.0
Response assessable	6	100.0	5	100.0
Failure-free	4	66.7	4	80.0	0.50 (0.03–9.46)	0.621e
Failure	2	33.3	1	20.0
Subgroup analyses of failure-free rate
Age
<70	10	62.5	15	93.8
≥70	11	73.3	14	87.5
Sex
Male	9	64.3	18	94.7
Female	12	70.6	11	84.6
WHO status
0	8	66.7	17	89.5
1	13	68.4	12	92.3
Stage
I or II	8	72.7	14	100.0
III	13	65.0	15	83.3
Total disease length
<5 cm	8	80.0	13	92.9
≥5 cm	13	61.9	16	88.9

^aTherefore no CT scan due at 24 weeks.

^bDone at 24 weeks ( ± 4 weeks) after start of treatment.

^cDone at 24 weeks (+12/-4 weeks) after start of treatment.

^dMixed effects logistic regression.

^eChi square.